The Company has assembled a talented team of proven entrepreneurs, experienced managers and scientists.
Casey P. Eitner, President/CEO, has extensive experience
starting and running successful new biotech businesses. Mr. Eitner
served as VP Business Development & New
Businesses at Life Technologies (Invitrogen). He was previously
Executive VP of the Molecular Diagnostics Division, now Digene
(DIGE), which pioneered
DNA-based diagnostic tests for papilloma virus and cervical cancer.
Biotech Venture Management LLC, which Mr. Eitner founded, has been
providing senior management roles to early stage biotech companies
in the
US, Canada
and Europe since 2000. He is also a director of CytoStore, Inc.
a spin-off from the University of Calgary.
David Krizman, Ph.D.,
Chief Scientific Officer, is a scientific co-founder of EPI. Dr.
Krizman has been a pioneer in applications
of novel genomics technologies to tissue while at the National
Human Genome
Research Institute and the National Cancer Institute. During
his time as a Principal Investigator at the NCI he co-founded
and led the Cancer
Genome Anatomy Project. Dr. Krizman has also served as a scientific
contractor and adviser at the Naval Research Laboratory.
Marlene Darfler, Vice President Product Development, is one
of the scientific co-founders. Ms. Darfler brings extensive
experience developing research and diagnostic tissue analysis
methods as a former senior research scientist at Invitrogen.
Peter Tunon, Vice President Sales and Marketing, brings over twenty years of expertise in driving new business and marketing programs. Mr. Tunon was previously Business Director at Life Technologies managing the BioSepra division, and Business Manager at Bio-Rad Laboratories where he managed the company’s chromatography consumables program.
Thomas G. Guiel, Vice President Operations, has experience starting up and managing research product and service operations. At Invitrogen, he was responsible for establishing global ordering and distribution, manufacturing operations and partnerships in Japan, New Zealand, Brazil, the U.K. and throughout the U.S.
Linda A. Broenniman, CFO, has a solid background as an executive in operations and financial management, primarily with emerging companies. She is an experienced entrepreneur, who founded and built a medical technology company as President/CEO. She has been CFO of a public company and her experience includes several M & A and capital transactions.
Expression
Pathology Inc. (EPI) is a leader in tissue
microproteomics. Our technologies make possible mass
spec protein analysis of formalin-fixed tissue,
enabling discovery, validation and routine
measurement of protein biomarkers related to clinical
outcomes. Our near-term mission is
to offer breakthrough research tools and
collaborations to improve drug and diagnostic development
and for basic research. Our proprietary
technologies also provide the foundation
for a whole new platform of tissue diagnostic tests currently
under development.
The Liquid Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire protein
content. Mass spec friendly. Requires only 30,000 cells for multiple
mass spectrometry analyses.
The Director™ Laser Microdissection Slides
provide the fastest, easiest and most accurate way to collect specific
cellular features from tissue sections. Engineered for use with existing
Leica LMD and PALM Zeiss laser microdissection system.
Investors
We are seeking investments and collaboration opportunities.
For more information please contact our business development group.
email
b u s d e v @ e x p ressi o n p a t h o l o g y d o t c o m
Transcribe email address to standard format. Spam bots have made
it impossible to post properly formatted email addresses.
